Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A detailed look at Epitalon's FDA regulatory status, compounding legality, safety data, and what the absence of an approved label means for prescribers and patients.
Read clinical reviewA detailed comparison of how the FDA and EMA view epitalon tetrapeptide, covering approval status, labeling, safety data, and what that means for clinical use in 2024.
Read clinical reviewA clinician-focused review of Epitalon FAERS safety signals, FDA regulatory status, absence of approved labeling, and what post-market surveillance data does and does not tell us about this unscheduled tetrapeptide.
Read clinical reviewEpitalon (Ala-Glu-Asp-Gly) has no FDA or EMA approval. Learn the current regulatory classification in the US, EU, Russia, Australia, and other markets, plus what the science actually shows.
Read clinical reviewA full regulatory and clinical review of epitalon tetrapeptide covering FDA status, no approved label, compounding restrictions, and published safety data from 2003 to 2026.
Read clinical reviewEpitalon (epithalon) has no FDA approval, no active U.S. patent protection, and no completed phase III trials. This article covers the peptide's regulatory status, legal gray areas, and what the clinical evidence actually supports.
Read clinical reviewEpitalon has no FDA approval and remains a research-only peptide. This article covers its regulatory status, published safety signals, clinical trial gaps, and the next-generation telomerase-targeting compounds in early development.
Read clinical review